AQT90 parameter guidelines
Several guidelines, standards and recommendations are relevant for specific users of the AQT90 FLEX analyzer
Use of troponin and/or CKMB
2007 consensus report on acute myocardial infarction definition made by a task force on behalf of ESC (European Society of Cardiology), ACCF (American College of Cardiology Foundation), AHA (American Heart Association) and WHF World Heart Federation).
In the new definition the use of cardiac biomarkers, preferably troponin, is still central in the diagnosis of myocardial infarction, together with ECG and patient history. An elevation of troponin (or another cardiac biomarker) combined with at least one of the following: ECG changes, imaging evidence or ischemia symptoms meet the criteria for a diagnosis of myocardial infarction:
Use of cardiac markers in the Emergency Department
Review piece including guidelines and recommendations on current cardiac markers in acute coronary syndrome and their role in therapeutic decisions, the best marker strategy, point-of-care assays and troponin cut-off values.
FDA on Troponin: What laboratorians should know to manage elevated results
The FDA document gives a good overview of potential causes for falsely elevated troponin values and lists some clinical conditions associated with truly elevated levels of cardiac troponin in the absence of myocardial infarction.
The document can be accessed here:
Use of D-dimer
The British Thoracic Society has guidelines for the use of a D-dimer test in patients suspected pulmonary embolism:
The American Academy of Family Physicians and the American College of Physicians has a guideline for the diagnosis of venous thromboembolism:
Use of BNP and/or NT-proBNP
2008 Guidelines for the diagnosis and treatment of heart failure made by a task force on behalf of ESC (European Society of Cardiology), the Heart Failure Association of the ESC (HFA) and indorsed by the European Society of Intensive Care Medicine (ESICM).
In addition, a comprehensive heart failure practice guideline was approved by the Heart Failure Society of America (HFSA) Executive Council in June 2010.
The natriuretic peptides (BNP and NT-proBNP) are especially useful in the diagnosis of heart failure.
Use of CRP
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults, written by the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Task Force on Practice Guidelines in collaboration with six other specialty societies can be found here:
In the Emergency Department
American College of Emergency Physicians provides a guideline for Emergency Department planning and resources: